AMBER WACHTARZ: Open Payments
NPI 1689256190 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$701 in 33 payments from 8 companies in 2025. Trend: 2023 $587 · 2024 $1,750 · 2025 $701
Food & beverage: $701
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $251 |
| E.R. Squibb & Sons, L.L.C. | 11 | $146 |
| PFIZER INC. | 5 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $74 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| HEARTFLOW, INC. | 1 | $27 |
| Novo Nordisk Inc | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
Products named: LEQVIO, VYNDAQEL, CAMZYOS, JARDIANCE, ELIQUIS, Kerendia, FFRct, Wegovy.
Industry payments across CT — which companies pay providers there.
